The target market for RECARDIO’s first project is AMI, followed by CHF.
Clinical safety of dutogliptin has been demonstrated in healthy humans as well as patients with Type 2 diabetes, the original target population for development of dutogliptin. After completion of the Phase 1 clinical study, the Phase 2B study in patients with AMI will start in 2018. Upon conclusion of this study RECARDIO intends to proceed into a Phase 3 clinical registration study for AMI and a Phase 2 clinical study in CHF patients.
The company’s intellectual property estate enables the efficient development of innovative cardiac therapies. National, international and priority forming recently issued patents and patent applications protect RECARDIO’s regenerative therapy program, using dutogliptin along with cytokines.